AngioDynamics vs Accuray
ANGO and ARAY side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANGO and ARAY compare
AngioDynamics is the larger company, worth 1.4 times as much as Accuray ($522M against $382M).
AngioDynamics grew revenue faster over the last twelve months (8.2% versus −12.5% for Accuray).
Accuray keeps more of each dollar of sales as profit, with a net margin of −4.4% compared with −10.1% at AngioDynamics.
AngioDynamics scores higher on the StockData Score (12 against 4 for Accuray), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANGO | ARAY |
|---|---|---|
| Size and price | ||
| Market cap | $522M | $382M |
| Share price | $12.42 | $3.20 |
| Change, 1 year | 1.1% | −93.2% |
| Change, 5 years | −56.5% | −98.5% |
| Beta (5Y) | 0.34 | 0.82 |
| Employees | 632 | 809 |
| StockData Score | ||
| Total score | 12 (better) | 4 |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 3 (better) | 2 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.6× | 1.0× (better) |
| P/B | 3.2× (better) | 7.2× |
| P/FCF | 362× | – |
| FCF yield | 0.28% (better) | −7.1% |
| Fair value | $13.23 | – |
| Margin of safety | 6.1% | – |
| Growth | ||
| Revenue growth (TTM) | 8.2% (better) | −12.5% |
| Revenue growth, 5Y average | 1.9% (better) | 0.28% |
| Profitability | ||
| Gross margin | 55.7% (better) | 28.0% |
| Operating margin | −11.2% (better) | −13.1% |
| Net margin | −10.1% | −4.4% (better) |
| FCF margin | 0.44% (better) | −6.9% |
| Return on equity | −19.2% (better) | −30.2% |
| Return on invested capital | −21.4% (better) | −30.9% |
| Financial health | ||
| Debt / equity | 0.00 | 1.91 (better) |
| Interest coverage | – | −1.4× |
| Current ratio | 2.40 (better) | 1.56 |
| Altman Z-score | 2.54 (better) | −0.45 |
| Piotroski F-score | 5 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 91.0% | 59.9% |
| Held by insiders | 5.8% | 28.7% |
| Insider net buying, 12 months | −$655K | $134K (better) |
| Short interest, % of float | 5.1% | 6.6% |
Go deeper
- ANGO stock overview
- ANGO income statement
- ANGO valuation and score
- ARAY stock overview
- ARAY income statement
- ARAY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.